O001/#504 Durvalumab, in combination with and following chemoradiotherapy, in locally advanced cervical cancer: results from the phase 3 international, randomized, double-blind, placebo-controlled calla trial
Bradley J. Monk(Florida Cancer Specialists & Research Institute), Jyoti Mayadev(University of California San Diego Medical Center), Umesh Mahantshetty(Homi Bhabha National Institute), Yulia Kreynina(Privolzhsky Research Medical University), M.H. Leiva Gálvez(Institute of Peruvian Studies), Juan Carlos Vázquez Limón(Harbin Medical University), Ana T. Nunes(AstraZeneca (United States)), Kathryn Howells(AstraZeneca (United States)), Masaki Mandai(Kyoto University), R. Tarnawski(The Maria Sklodowska-Curie National Research Institute of Oncology), Ronnie Shapira‐Frommer(Sheba Medical Center), Hannah Dry(AstraZeneca (United States)), Francisco Ramirez Godinez(Hospital Civil de Guadalajara), Jung‐Yun Lee(Yonsei University), Maria Del Pilar Estevez-Diz(International Organization for Migration), Qi Zhou(Chongqing University), Xiaohua Wu(Fudan University Shanghai Cancer Center), Sophie Wildsmith(AstraZeneca (United Kingdom)), Szilvia Varga(National Institute of Oncology), Takafumi Toita(Okinawa Prefectural Chubu Hospital)
Cited by 15
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
|Journal of Clinical Oncology|2000|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k